« Back
Home /
Pevonedistat

Pevonedistat

Item no.	HY-70062-100mg
Manufacturer	MedChem Express
CASRN	905579-51-3
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009 Apr 9;458(7239):732-6.\|[2]F S Wolenski, et al. The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. Cell Death Discovery 1, Article number: 15034 (2015) Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L104-L114.\|Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1070-L1080. \|Ann Hematol. 2014 Sep;93(9):1499-508.\|Arch Biochem Biophys. 2021 Jul 31;109000.\|Arch Biochem Biophys. 2022 May 30;721:109194.\|Bioact Mater. 2024 Apr, 34, Pages 366-380.\|Biochem Biophys Res Commun. 2017 Jan 29;483(1):223-229. \|Biochem Biophys Res Commun. 2018 Nov 17;506(1):108-113. \|Biochem Biophys Res Commun. 2019 Sep 3;516(4):1242-1247. \|Biochem Biophys Res Commun. 2021 Mar 3;549:150-156.\|Biochem Biophys Res Commun. 2019 Jan 15;508(3):986-990. \|Biochem Pharmacol. 2024 May:223:116198.\|Bioorg Chem. 2024 Jun 24:150:107590.\|bioRxiv. 2023 Feb 15.\|bioRxiv. 2023 Feb 23.\|bioRxiv. 2023 Jun 5.\|bioRxiv. 2024 Jan 28.\|bioRxiv. 2024 July 08.\|bioRxiv. 2024 June 12.\|bioRxiv. 2024 November 28.\|bioRxiv. 2024 Sep 27:2024.09.25.615094.\|bioRxiv. 2024 September 19.\|bioRxiv. 2024 September 26.\|bioRxiv. 2025 January 08.\|bioRxiv. April.\|Biosci Biotechnol Biochem. 2024 Sep 27:zbae131.\|Biosci Rep. 2022 Jul 26;BSR20220994.\|Cancer Cell. 2020 Mar 16;37(3):371-386.e12.\|Cancer Chemother Pharmacol. 2018 Jun;81(6):1083-1093.\|Cancers. 2019 Jan 15;11(1):97.\|Cell Biol Toxicol. 2025 Mar 20;41(1):61.\|Cell Biosci. 2020 Nov 27;10(1):139.\|Cell Chem Biol. 2021 Jul 15;S2451-9456(21)00312-3.\|Cell Cycle. 2019 Sep;18(18):2307-2322.\|Cell Death Differ. 2020 Apr;27(4):1383-1397. \|Cell Death Differ. 2021 Jul 2.\|Cell Death Discov. 2022 Jul 12;8(1):316.\|Cell Death Discov. 2022 May 2;8(1):238.\|Cell Death Discov. 2024 Oct 26;10(1):453.\|Cell Metab. 2023 Sep 5;35(9):1630-1645.e5.\|Cell Rep Med. 2024 Jul 16;5(7):101653.\|Cell Rep. 2021 Aug 24;36(8):109568.\|Cell Rep. 2021 Jul 20;36(3):109394.\|Cell Rep. 2024 Feb 27;43(2):113749.\|Cell Res. 2021 Mar;31(3):291-311.\|Cell Signal. 2025 Feb 20:111665.\|Cell Stem Cell. 2024 Jun 21:S1934-5909(24)00210-8.\|Cell. 2019 Jul 11;178(2):330-345.e22.\|Cell. 2023 Apr 27;186(9):1895-1911.e21.\|Cells. 2020 Mar 30;9(4):834.\|Cells. 2021, 10(11), 2803.\|Clin Transl Med. 2020 Jun;10(2):e113.\|Commun Biol. 2021 Sep 13;4(1):1066.\|Comput Struct Biotechnol J. 1 October 2021.\|Dev Cell. 2019 Feb 11;48(3):329-344.e5.\|Elife. 2016 Apr 11;5:e14087.\|Elife. 2018 Aug 1;7:e38430. \|Elife. 2020 Jun 2;9:e54954.\|Elife. 2019 Mar 25;8:e45457. \|EMBO J. 2019 Dec 2;38(23):e101409.\|EMBO Rep. 2025 Feb 6.\|Eur J Med Chem. 2023 Aug 19, 115732.\|Eur J Pharmacol. 2025 Jan 9:177270.\|Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280.\|Exp Cell Res. 2020 Jul 15;392(2):112038.\|FASEB J. 2021 Aug;35(8):e21800.\|Front Cell Dev Biol. 2021 Apr 30.\|Front Cell Dev Biol. 2021 Apr 30;9:667435.\|Front Immunol. 2022 Jul 4;13:925702.\|Front Oncol. 2017 Dec 11;7:293.\|Front Oncol. 2022 Jan 26;12:822039.\|Harvard University. 2023 Mar. 30487357.\|Inflammation. 2025 Mar 1.\|Institut für Pharmazeutische Wissenschaften. 2020 Nov.\|Institute of Molecular Virology. Ulm University. 2017 Jan.\|Int Immunopharmacol. 2024 Jul 21:139:112716.\|Int J Biol Macromol. 2024 Sep 17:135764.\|Int J Biol Macromol. 2025 Mar 1:141587.\|Int J Med Sci. 2018 Apr 3;15(7):674-681.\|Int J Mol Sci. 2023, 24(4), 3415.\|iScience. 2023 Mar.\|J Anim Sci. 2024 Aug 27.\|J Biol Chem. 15 October 2021, 101307.\|J Biol Chem. 2022 Sep 12;102484.\|J Biol Chem. 2024 Jul 1:107512.\|J Cell Physiol. 2022 May 16.\|J Cell Physiol. 2024 Oct 7:e31459.\|J Exp Med. 2018 Aug 6;215(8):1999-2017. \|J Immunol. 2021 Jun 28;ji2001167.\|J Med Chem. 2021 Dec 29.\|J Med Chem. 2021 Jun 17.\|J Med Chem. 2023 Jun 30.\|J Med Chem. 2023 Mar 9.\|J Med Chem. 2023 Sep 6.\|J Med Chem. 2024 Jul 24.\|J Med Chem. 2024 Oct 10.\|J Med Chem. 2024 Oct 15.\|J Virol. 2022 May 25;96(10):e0059822.\|J Virol. 2024 Feb 20;98(2):e0190923.\|Lab Invest. 2019 Apr;99(4):528-538.\|Mbio. 2020 Jul 14;11(4):e00782-20.\|Mol Cancer Res. 2023 Feb 8;MCR-22-0648.\|Mol Cell. 2022 Feb 17;S1097-2765(22)00085-5.\|Mol Cell. 2023 Nov 16:S1097-2765(23)00913-9.\|Mol Metab. 2021 Jun 18;101275.\|Mol Ther Oncolytics. 2020 Jun 23;18:215-225.\|Nat Chem Biol. 2023 Aug 31.\|Nat Chem Biol. 2023 Sep 7.\|Nat Chem Biol. 2024 Jul 29.\|Nat Chem Biol. 2024 Mar 21.\|Nat Commun. 2017 May 22;8:15398. \|Nat Commun. 2018 Sep 18;9(1):3801. \|Nat Commun. 2021 Sep 10;12(1):5386.\|Nat Commun. 2022 Oct 10;13(1):5973.\|Nat Commun. 2022 Sep 2;13(1):5173.\|Nat Commun. 2024 Aug 17;15(1):7089.\|Nat Commun. 2024 Dec 3;15(1):10536.\|Nat Commun. 2024 Jan 11;15(1):468.\|Nat Commun. 2024 Jul 3;15(1):5604.\|Nat Commun. 2024 Jun 26;15(1):5409.\|Nat Microbiol. 2019 May;4(5):813-825.\|Nat Plants. 2019 Jan;5(1):34-40. \|Nat Struct Mol Biol. 2024 Jan 4.\|Nature Cancer. 2021 Apr;2(4):429-443.\|Nature. 2020 Dec;588(7836):164-168.\|Nature. 2025 Feb;638(8050):519-527.\|Neoplasia. 2022 Jul 27;32:100823.\|Neurobiol Dis. 2020 Sep;143:105013.\|Oncol Lett. 2019 Sep;18(3):2724-2732. \|Oncotarget. 2016 Jun 14;7(24):35643-35654.\|Oncotarget. 2016 Oct 4;7(40):66087-66099.\|Oncotarget. 2017 Sep 23;8(49):86395-86409. \|Patent. US20180263995A1.\|Patent. US20220175722A1.\|Patent. US20220280649A1.\|Patent. US20220281931A1.\|Patent. US20220378919A1.\|Patent. US20240190838A1.\|Pharmaceuticals. 2024 May 11.\|Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2111737119.\|Protein Sci. 2021 Aug 30.\|Redox Biol. 2021 Aug 24;46:102114.\|Research Square Preprint. 2021 Jun.\|Research Square Preprint. 2022 Jul.\|Research Square Print. 2022.\|Sci Adv. 2024 Apr 12;10(15):eadm7600.\|Sci Signal. 2025 Feb 11.\|Signal Transduct Target Ther. 2024 Jan 15;9(1):18.\|Technol Cancer Res Treat. 2016 Aug;15(4):527-34. \|Theriogenology. 2025 Feb 18:237:99-109.\|University of Colorado Denver. 2024.\|University of Southern California. 2024.\|Virology. 2015 Mar;477:10-7. \|Viruses. 2023 Nov 30, 15(12), 2356.\|bioRxiv. 2024 July 01.\|Harvard Medical School LINCS LIBRARY\|J Pathol. 2021 Feb 27.\|Oncotarget. 2017 Oct 12;8(57):97178-97186. \|Sci Adv. 2022 Sep 23;8(38):eabq4831.
Smiles	O=S(OC[C@@H]1C[C@@H](N2C3=NC=NC(N[C@H]4CCC5=C4C=CC=C5)=C3C=C2)C[C@@H]1O)(N)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MLN4924
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; NEDD8-activating Enzyme
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	443.52
Product Description	Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM. Pevonedistat induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat suppresses the growth of human tumour xenografts in mice[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 62.5 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Metabolic Enzyme/Protease
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-70062-100mg-safety-datasheet.pdf